Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Kenvue Inc. (NYSE:KVUE)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Kenvue stock on March 13th.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Kenvue Price Performance

NYSE:KVUE traded down $0.03 during mid-day trading on Thursday, reaching $17.32. The stock had a trading volume of 4,104,369 shares, compared to its average volume of 39,236,418. The firm has a 50 day moving average price of $17.96 and a two-hundred day moving average price of $17.06. The stock has a market capitalization of $33.19 billion, a P/E ratio of 22.49, a P/E/G ratio of 3.89 and a beta of 0.61. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. The company had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.Kenvue’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS. As a group, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were given a $0.2075 dividend. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s payout ratio is presently 107.79%.

Hedge Funds Weigh In On Kenvue

Large investors have recently bought and sold shares of the stock. Salomon & Ludwin LLC purchased a new stake in Kenvue in the third quarter worth $25,000. NBT Bank N A NY increased its position in Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after purchasing an additional 1,006 shares during the period. Cornerstone Planning Group LLC lifted its position in shares of Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares during the period. Physician Wealth Advisors Inc. lifted its position in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the period. Finally, Elyxium Wealth LLC bought a new stake in shares of Kenvue during the 4th quarter valued at about $26,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

KVUE has been the subject of a number of recent research reports. UBS Group dropped their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday. Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Barclays lifted their price target on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Friday, March 6th. Argus raised Kenvue to a “hold” rating in a research note on Friday, March 6th. Finally, Canaccord Genuity Group lifted their price target on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Three equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $19.50.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.